DK359284A - Mevalolactonanaloge - Google Patents
Mevalolactonanaloge Download PDFInfo
- Publication number
- DK359284A DK359284A DK359284A DK359284A DK359284A DK 359284 A DK359284 A DK 359284A DK 359284 A DK359284 A DK 359284A DK 359284 A DK359284 A DK 359284A DK 359284 A DK359284 A DK 359284A
- Authority
- DK
- Denmark
- Prior art keywords
- hydrogen
- benzyloxy
- phenoxy
- trifluoromethyl
- fluoro
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
- -1 t-butoxy Chemical group 0.000 abstract 6
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44366882A | 1982-11-22 | 1982-11-22 | |
US54885083A | 1983-11-04 | 1983-11-04 | |
PCT/EP1983/000308 WO1984002131A1 (en) | 1982-11-22 | 1983-11-18 | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
Publications (2)
Publication Number | Publication Date |
---|---|
DK359284A true DK359284A (da) | 1984-07-20 |
DK359284D0 DK359284D0 (da) | 1984-07-20 |
Family
ID=27033614
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK359284A DK359284D0 (da) | 1982-11-22 | 1984-07-20 | Mevalolactonanaloge |
DK097890A DK165244C (da) | 1982-11-22 | 1990-04-19 | Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK097890A DK165244C (da) | 1982-11-22 | 1990-04-19 | Analogifremgangsmaade til fremstilling af 1,2,3-trisubstituerede indoler |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0114027B1 (da) |
JP (1) | JPH0347167A (da) |
AT (1) | ATE31718T1 (da) |
AU (1) | AU570021B2 (da) |
CA (1) | CA1210405A (da) |
CY (1) | CY1579A (da) |
DE (2) | DE3375137D1 (da) |
DK (2) | DK359284D0 (da) |
FI (1) | FI77228C (da) |
GR (1) | GR79042B (da) |
HK (1) | HK11191A (da) |
HU (1) | HU204253B (da) |
IE (1) | IE56262B1 (da) |
IL (1) | IL70286A (da) |
LU (1) | LU88670I2 (da) |
NL (1) | NL950022I2 (da) |
NZ (1) | NZ206338A (da) |
WO (1) | WO1984002131A1 (da) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4613610A (en) * | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
DE3581638D1 (de) * | 1984-12-04 | 1991-03-07 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
US5001255A (en) * | 1984-12-04 | 1991-03-19 | Sandoz Pharm. Corp. | Idene analogs of mevalonolactone and derivatives thereof |
US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
US4851427A (en) * | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
KR900001212B1 (ko) * | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도 |
NZ221717A (en) * | 1986-09-10 | 1990-08-28 | Sandoz Ltd | Azaindole and indolizine derivatives and pharmaceutical compositions |
US4751235A (en) * | 1986-12-23 | 1988-06-14 | Sandoz Pharm. Corp. | Anti-atherosclerotic indolizine derivatives |
US4735958A (en) * | 1986-12-22 | 1988-04-05 | Warner-Lambert Company | Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis |
US4897490A (en) * | 1987-02-25 | 1990-01-30 | Bristol-Meyers Company | Antihypercholesterolemic tetrazole compounds |
US4898949A (en) * | 1987-02-25 | 1990-02-06 | Bristol-Myers Company | Intermediates for the preparation of antihypercholesterolemic tetrazole compounds |
US4894386A (en) * | 1987-04-15 | 1990-01-16 | Ici Americas Inc. | Aliphatic carboxamides |
US4904646A (en) * | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
US5091378A (en) * | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US5185328A (en) * | 1987-08-20 | 1993-02-09 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
DE3739882A1 (de) * | 1987-11-25 | 1989-06-08 | Bayer Ag | Substituierte hydroxylamine |
US4868185A (en) * | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
HU202842B (en) * | 1988-01-27 | 1991-04-29 | May & Baker Ltd | Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them |
US4822799A (en) * | 1988-01-27 | 1989-04-18 | Sandoz Pharm. Corp. | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals |
NO890522L (no) * | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte imidazolinoner og imidazolinthioner. |
US5024999A (en) * | 1988-04-26 | 1991-06-18 | Nissan Chemical Industries Ltd. | Pyrazolopyridine type mevalonolactones useful as pharmaeuticals |
JP2890448B2 (ja) * | 1988-04-26 | 1999-05-17 | 日産化学工業株式会社 | ピラゾロピリジン系メバロノラクトン類 |
US5010205A (en) * | 1988-08-23 | 1991-04-23 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl intermediates |
US4870187A (en) * | 1988-08-23 | 1989-09-26 | Bristol-Myers Company | Antihypercholesterolemic tetrazol-1-yl compounds |
NZ230121A (en) * | 1988-08-29 | 1993-08-26 | Squibb & Sons Inc | Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels |
US5506219A (en) * | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
IE940109L (en) * | 1988-10-13 | 1990-04-13 | Sandoz Ag | 7-substituted-hept-6-enoic and -heptanoic acids and¹derivatives thereof |
JPH04270285A (ja) * | 1988-11-14 | 1992-09-25 | Nissan Chem Ind Ltd | ピラゾロピリミジン系メバロノラクトン類 |
DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB8919091D0 (en) * | 1989-08-22 | 1989-10-04 | Fujisawa Pharmaceutical Co | Pyrroloquinoline compounds |
IT1237792B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
DE4243279A1 (de) * | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
JP2736599B2 (ja) * | 1993-07-23 | 1998-04-02 | 株式会社キッツ | ボールバルブのシート構造 |
US6425881B1 (en) | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
WO1997049681A1 (en) * | 1996-06-24 | 1997-12-31 | Astra Aktiebolag (Publ) | Polymorphic compounds |
WO1998055454A2 (en) | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Benzofurans and benzothophenes as suppressors of neurodegeneration |
RU2233654C2 (ru) | 1998-11-20 | 2004-08-10 | Ртп Фарма Инк. | Диспергируемые стабилизированные фосфолипидом микрочастицы |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US6743926B2 (en) | 2000-05-26 | 2004-06-01 | Ciba Specialty Chemicals Corporation | Process for the preparation of indole derivatives and intermediates of the process |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
AU2002257147B9 (en) | 2001-04-18 | 2005-08-18 | Genzyme Corporation | Methods of treating syndrome X with aliphatic polyamines |
EP1429757B8 (en) * | 2001-08-03 | 2008-07-16 | Ciba Holding Inc. | Crystalline forms of fluvastatin sodium |
AU2002367060A1 (en) | 2001-12-21 | 2003-07-30 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
CA2480879A1 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2004266740B2 (en) | 2003-08-21 | 2010-08-26 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
CN100404479C (zh) * | 2003-08-27 | 2008-07-23 | 住友化学株式会社 | 芳族不饱和化合物的制备方法 |
US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
US7709508B2 (en) | 2004-12-09 | 2010-05-04 | Merck Sharp & Dohme | Estrogen receptor modulators |
RU2394820C2 (ru) | 2004-12-09 | 2010-07-20 | Мерк Шарп Энд Домэ Корп. | Модуляторы рецептора эстрогена |
DK1855674T3 (da) | 2005-03-02 | 2014-10-20 | Merck Sharp & Dohme | Sammensætning til hæmning af cathepsin k |
KR101363278B1 (ko) | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
WO2007017117A1 (en) * | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
US8440695B2 (en) | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
PL2010528T3 (pl) | 2006-04-19 | 2018-03-30 | Novartis Ag | 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r |
EP1847529B1 (en) | 2006-04-20 | 2009-05-20 | F.I.S. Fabbrica Italiana Sintetici S.P.A. | Process for the preparation of Fluvastatin Sodium salt |
CN102772411A (zh) | 2006-07-05 | 2012-11-14 | 奈科明有限责任公司 | 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合 |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
EP2132177B1 (en) | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
KR20100017866A (ko) | 2007-05-21 | 2010-02-16 | 노파르티스 아게 | Csf-1r 억제제, 조성물 및 사용 방법 |
ES2330184B1 (es) | 2008-06-03 | 2010-07-05 | Neuron Biopharma, S.A. | Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores. |
EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
EP2373609B1 (en) | 2008-12-19 | 2013-10-16 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
PT2435410T (pt) | 2009-05-28 | 2017-05-03 | Bristol Myers Squibb Co | Resumo |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
JP2013522292A (ja) | 2010-03-16 | 2013-06-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | インダゾール化合物およびそれらの使用 |
US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
EP2626069A4 (en) | 2010-10-06 | 2014-03-19 | Univ Tokyo | A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH |
US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
WO2013102193A1 (en) | 2011-12-29 | 2013-07-04 | Trustees Of Tufts College | Functionalization of biomaterials to control regeneration and inflammation responses |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
CN105209039B (zh) | 2013-03-15 | 2018-06-22 | 百时美施贵宝公司 | Lxr调节剂 |
EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
CA2923272A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015120580A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
-
1983
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/de active IP Right Grant
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 CA CA000441684A patent/CA1210405A/en not_active Expired
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 EP EP83810548A patent/EP0114027B1/en not_active Expired
-
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284D0/da not_active Application Discontinuation
-
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
-
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
-
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DE19475017I2 (de) | 2003-02-20 |
ATE31718T1 (de) | 1988-01-15 |
GR79042B (da) | 1984-10-02 |
DK165244B (da) | 1992-10-26 |
DK97890D0 (da) | 1990-04-19 |
EP0114027A1 (en) | 1984-07-25 |
IE56262B1 (en) | 1991-06-05 |
DE3375137D1 (en) | 1988-02-11 |
NL950022I1 (da) | 1996-01-02 |
JPH0440343B2 (da) | 1992-07-02 |
LU88670I2 (fr) | 1996-04-29 |
FI77228B (fi) | 1988-10-31 |
CA1210405A (en) | 1986-08-26 |
HU204253B (en) | 1991-12-30 |
WO1984002131A1 (en) | 1984-06-07 |
FI842615A (fi) | 1984-06-28 |
FI77228C (fi) | 1989-02-10 |
AU570021B2 (en) | 1988-03-03 |
DK97890A (da) | 1990-04-19 |
EP0114027B1 (en) | 1988-01-07 |
HUT35642A (en) | 1985-07-29 |
HK11191A (en) | 1991-02-13 |
DK165244C (da) | 1993-03-22 |
JPH0347167A (ja) | 1991-02-28 |
AU2261283A (en) | 1984-06-18 |
IL70286A (en) | 1987-08-31 |
DK359284D0 (da) | 1984-07-20 |
FI842615A0 (fi) | 1984-06-28 |
NL950022I2 (nl) | 1996-12-02 |
CY1579A (en) | 1991-12-20 |
IL70286A0 (en) | 1984-02-29 |
IE832713L (en) | 1984-05-22 |
NZ206338A (en) | 1987-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK359284D0 (da) | Mevalolactonanaloge | |
NZ214402A (en) | Indene derivatives and pharmaceutical compositions | |
ATE181482T1 (de) | Herbizide zusammensetzungen in form einer diphenylether- und stickstofflösung und verfahren | |
AU537414B2 (en) | Pyroglutamic acid derivatives | |
ES8102561A1 (es) | Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles | |
IE840153L (en) | Mevalonolactone analogues and related hydroxy acids for¹control of blood cholesterol levels. | |
ES2010284A6 (es) | Procedimiento para preparar derivados de tiourea. | |
ES8708220A1 (es) | Procedimiento para la obtencion de halogeno-hidroxi-flavonas | |
ES8704918A1 (es) | Un procedimiento para la preparacion de nuevos derivados de esteres fosforicos. | |
ES8403882A1 (es) | Un procedimiento para preparar esteres heterociclicos de acidos fenoxibenzoicos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ARF | Application refused |